Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Iradimed (IRMD) over the last 7 years, with Q3 2025 value amounting to $12.9 million.

  • Iradimed's Shares Outstanding (Diluted Average) rose 63.88% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 63.88%. This contributed to the annual value of $12.8 million for FY2024, which is 47.97% up from last year.
  • Iradimed's Shares Outstanding (Diluted Average) amounted to $12.9 million in Q3 2025, which was up 63.88% from $12.8 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Shares Outstanding (Diluted Average) registered a high of $12.9 million during Q3 2025, and its lowest value of $12.6 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $12.7 million (2023), whereas its average is $12.7 million.
  • In the last 5 years, Iradimed's Shares Outstanding (Diluted Average) soared by 121.19% in 2021 and then increased by 24.64% in 2023.
  • Iradimed's Shares Outstanding (Diluted Average) (Quarter) stood at $12.6 million in 2021, then rose by 0.36% to $12.6 million in 2022, then grew by 0.69% to $12.7 million in 2023, then increased by 0.48% to $12.8 million in 2024, then increased by 0.6% to $12.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $12.9 million for Q3 2025, versus $12.8 million for Q2 2025 and $12.8 million for Q1 2025.